Background In 2013 a rubella outbreak occurred among Japanese people of working-age
which resulted in 14,357 reported cases. The Japanese government subsequently …

Vaccination policy in the case of human papillomavirus (HPV) has remained a constant
source of controversy ever since Gardasil, Merck's vaccine against HPV, received US Food …

In Japan, government subsidies for human papillomavirus (HPV) vaccination of girls aged
13–16 commenced in 2010. By early 2013, vaccination had become a widely accepted …

Abstract Aim In Japan, in 2013, following reports of several alleged adverse reactions in
young girls following vaccination, the previously successful national human papillomavirus …

Vaccination coverage is the result of a complex interplay between different stakeholders with
a specific societal and cultural background. The goal of this poster is to provide a brief …

Human papillomavirus (HPV)-related morbidity and mortality from cervical cancer primarily
occurs in the developing world, where, unfortunately, access to vaccines in general, and …

This study aimed to identify the factors predicting rubella vaccination status based on self-
reported data and the presence of sufficient rubella antibody titers in pregnant women in …

Abstract The Human Papillomavirus (HPV) vaccine was integrated into Japan's national
immunization program (NIP) in April 2013. However, numerous instances of serious adverse …

In Japan, cervical cancer has the highest incidence rate among cancers affecting women
aged 15–39, with human papillomavirus (HPV) infection reported as the primary cause. 1 …

BACKGROUND: In Japan, the bivalent HPV vaccine was approved in October, 2009 and
became available as a non-routine vaccine from December, 2009. While routine …